

Haematologica
HAEMATOL/2018/209031
Version 3

Convergence of risk prediction models in follicular lymphoma

Anjali Silva, Sleiman Bassim, Clémentine Sarkozy, Anja Mottok, Tracy Lackraj, Vindi Jurinovic, Marianne Brodtkorb, Ole Christian Lingjaerde, Laurie H. Sehn, Randy D. Gascoyne, Oliver Weigert, Christian Steidl, and Robert Kridel

Disclosures: 1. This work was supported by a Terry Fox Research Institute New Investigator Award (Grant #1079), a Leukemia & Lymphoma Society of Canada Operating Grant (Grant #513421) and the Princess Margaret Cancer Foundation. 2. Laurie Sehn - Consultancy and Honoraria from Roche/Genentech, Abbvie, Amgen, Celgene, Janssen, Lundbeck, Seattle Genetics, Merck, TG Therapeutics, Morphosys, and Karyopharm; Clémentine Sarkozy - Travel support from Takeda (for ASH 2016), research funding from Takeda and Roche/Genentech, honoraria from Roche / Genentech and Celgene; Randy D. Gascoyne - consulting for Roche; Oliver Weigert - Roche and Novartis: research support for work outside of submitted work; Christian Steidl - Consulting for Hoffmann-La Roche, Seattle Genetics and Affimed Therapeutics; expert testimony for Juno Therapeutics. Research funding: BMS, Tioma; Robert Kridel - Travel support from Roche. Research funding from Gilead.

Contributions: A.S. and R.K. designed the research, analyzed the data, and wrote the manuscript; A.M. and R.K. performed the research; S.B., T. L., V. J., M. B., O. C. L., L.H.S., R.D.G., O.W. and C.S., collected and contributed samples and data. All authors approved the final manuscript draft.